Benitec Biopharma INC Form 4 insider transactions

Director J. Kevin Buchi reported a disposition of 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised charitable fund.

Director David Matthew Friedman was granted 35,000 stock options as part of his board compensation at Benitec Biopharma.

Benitec Biopharma Inc. Director Sharon Mates was granted 31,500 stock options with an exercise price of $12.83, set to vest by December 1, 2026.

Suvretta Capital Management and its affiliated funds significantly increased their beneficial ownership in Benitec Biopharma Inc. through open market purchases.

Suvretta Capital Management and its affiliated funds increased their beneficial ownership in Benitec Biopharma Inc. through multiple open market purchases in December 2025.

Benitec Biopharma Inc. Director Edward F. Smith was granted 35,000 stock options with an exercise price of $12.23, which will vest by December 1, 2026.

Benitec Biopharma Inc. Director Sharon Mates acquired 3,500 stock options with an exercise price of $12.23, vesting by December 2026.

Benitec Biopharma Director Kishan Mehta was awarded 35,000 stock options with an exercise price of $12.23, vesting by December 2026.

Benitec Biopharma Inc. Director Peter Francis was granted 35,000 stock options with an exercise price of $12.23, vesting by December 2026.

Benitec Biopharma Inc. Director J. Kevin Buchi was granted 35,000 stock options with an exercise price of $12.23, vesting by December 2026.

Benitec Biopharma's Chief Operating Officer, Sophie Mukadam, was granted 500,000 stock options with an exercise price of $13.53.

Benitec Biopharma Inc. CEO Jerel A. Banks was granted 450,000 stock options with an exercise price of $13.53, vesting quarterly starting March 2026.

Benitec Biopharma's Chief Financial Officer and Director, Megan Boston, acquired 200,000 stock options with an exercise price of $13.53, vesting quarterly from March 2026.

Suvretta Capital Management and its affiliated funds have significantly increased their beneficial ownership in Benitec Biopharma Inc. through a $20 million stock purchase.

Benitec Biopharma Director Sharon Mates acquired 28,517 stock options with an exercise price of $15.78, vesting by November 2026.

Suvretta Capital Management, along with related entities and individuals, reports acquiring additional shares of Benitec Biopharma Inc., increasing their beneficial ownership.

Suvretta Capital Management, along with affiliated funds and Aaron Cowen, report increased ownership in Benitec Biopharma Inc. through recent stock purchases.

Director J. Kevin Buchi reported gifting 103,626 shares of Benitec Biopharma Inc. common stock to a trust on March 12, 2025.

J. Kevin Buchi, a director of Benitec Biopharma Inc., exercised warrants to acquire 51,813 shares of common stock and disposed of the same amount on February 27, 2025.

Suvretta Capital Management, along with Averill Master Fund, Averill Madison Master Fund, and Aaron Cowen, reported increased beneficial ownership of Benitec Biopharma Inc. common stock through open market purchases.

Benitec Biopharma Inc. granted stock options to board member Kishan Mehta, which will vest no later than December 9, 2025.

Benitec Biopharma Inc. granted stock options to Peter Francis, exercisable for 35,000 shares of common stock, vesting no later than December 9, 2025.

Benitec Biopharma Inc. has granted stock options to J. Kevin Buchi, exercisable for 35,000 shares of common stock, vesting no later than December 9, 2025.

Benitec Biopharma Inc. grants stock options to executive Edward Smith, vesting upon the next annual stockholders' meeting or December 9, 2025.

Benitec Biopharma's CEO, Jerel A. Banks, has been granted 2.31 million stock options that will vest quarterly starting March 31, 2025.

Benitec Biopharma has granted its Executive Director, Megan Boston, 720,000 stock options that will vest quarterly starting March 31, 2025.

Suvretta Capital Management and related entities have reported purchasing additional shares of Benitec Biopharma, increasing their holdings.

Suvretta Capital Management and its affiliated funds have increased their holdings in Benitec Biopharma through a series of open market purchases of common stock.

Suvretta Capital Management, along with affiliated funds and individuals, filed a Form 4 disclosing changes in their beneficial ownership of Benitec Biopharma Inc. common stock and warrants due to warrant exercises.

Benitec Biopharma Inc. CEO Jerel A. Banks reports acquiring options to purchase 466,554 shares of common stock.